Quarterly report pursuant to Section 13 or 15(d)

Note 4 - Acquisitions - Preliminary and Final Fair Value of Assets and Liabilities Assumed (Details)

v3.21.1
Note 4 - Acquisitions - Preliminary and Final Fair Value of Assets and Liabilities Assumed (Details) - USD ($)
$ in Thousands
5 Months Ended 9 Months Ended
Oct. 20, 2020
Mar. 31, 2021
Mar. 31, 2021
Mar. 31, 2020
Dec. 31, 2020
Jun. 30, 2020
Goodwill   $ 746,460 $ 746,460   $ 728,310 $ 728,308
Payments to Acquire Businesses, Net of Cash Acquired, Total     9,765 $ (0)    
Changzhou Eminence Biotechnology [Member]            
Current assets, net of cash $ 3,145 3,145 3,145      
Equipment and other long-term assets 1,639 1,639 1,639      
Goodwill 8,811 7,848 7,848      
Goodwill, Purchase Accounting Adjustments   (963)        
Total assets acquired 22,506 21,543 21,543      
Total assets acquired   (963)        
Liabilities 1,436 1,436 1,436      
Deferred income taxes, net 2,320 1,357 1,357      
Deferred income taxes, net   (963)        
Net assets acquired 18,750 18,750 18,750      
Payments to Acquire Businesses, Net of Cash Acquired, Total 9,765          
Business Combination, Acquisition of Less than 100 Percent, Noncontrolling Interest, Fair Value 8,985 8,985 8,985      
Net assets acquired 18,750          
Changzhou Eminence Biotechnology [Member] | Developed Technology Rights [Member]            
Intangible assets 6,778 6,778 6,778      
Changzhou Eminence Biotechnology [Member] | Customer Relationships [Member]            
Intangible assets $ 2,133 $ 2,133 $ 2,133